PharmAbcine Announces First Patient Enrolled and Dosed in the Phase II Clinical Trial for the Treatment of mTNBC
DAEJEON, South Korea, Dec. 27, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, today announced it has dosed the first patient in its Phase II clinical trial evaluating the combination of olinvacimab, PharmAbcine's anti-VEGFR2 (Vascular Endothelial Growth Factor Receptors) antibody, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 molecule, for the treatment of mTNBC (metastatic Triple-Negative Breast Cancer) in Australia.
The Phase II clinical trial is currently open and actively recruiting patients. It is an open-label and multicenter trial that will enroll 36 immuno-oncology drug naïve mTNBC patients regardless of their PD-L1 expression level. The study is designed to evaluate the clinical efficacy, safety, pharmacodynamics, and the expression level of VEGFR2. The enrolled patients will be treated with 16mg/kg of olinvacimab every week and 200mg of pembrolizumab every 3 weeks for up to 35 cycles (approximately 2 years).
Both companies decided to initiate this study based on the promising clinical data obtained from the Phase Ib olinvacimab and pembrolizumab study in mTNBC which is still ongoing in Australia. According to the interim result presented at SABCS (San Antonio Breast Cancer Symposium) 2020, olinvacimab in combination with pembrolizumab showed a clear safety profile and encouraging efficacy data, including 50% ORR (Overall Response Rate) and 67% DCR (Disease Control Rate) in the high-dose olinvacimab (16mg/kg) cohort (n=6pts). In addition, one patient in PR (Partial Response) showed CR (Complete Response) in the target lesion and another PR patient showed CR in a non-target lesion.
mTNBC is a highly malignant type of cancer that shows a high recurrence rate within the first five years after diagnosis. mTNBC accounts for 15-20% of all breast cancers and shows a 5-year survival rate of approximately 11%. Unlike other breast cancers, mTNBC does not express estrogen or progesterone receptors or HER2 (human epidermal growth factor receptor 2), and it does not respond to existing cancer drugs designed to target these markers. mTNBC is very difficult to treat, and there are very few FDA approved treatment options for these patients.
Olinvacimab is the Company's leading pipeline and is undergoing multiple global clinical trials. Other than the ongoing Phase II olinvacimab and pembrolizumab combo trial in mTNBC, a Phase II olinvacimab mono study for bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients is ongoing at multiple sites in both US and Australia. Also, two Phase Ib olinvacimab and pembrolizumab combo trials in mTNBC and rGBM in Australia are still ongoing.
"We are pleased to have commenced the first enrollment and dosing in this important study," said Professor. Arlene Chan, the principal investigator of this study and a medical oncologist at Hollywood Private Hospital in Western Australia. "The encouraging clinical results and the excellent safety profile from the previous Phase Ib trial gave us huge confidence in the Phase II study. We hope to see this combination therapy rise up as a promising treatment option for mTNBC patients in which current treatment options are limited."
"It is thrilling to have reached this important milestone as this study is critical towards offering a potential new treatment for the mTNBC patients," said Dr. Jin-San Yoo, CEO of PharmAbcine. "PharmAbcine is grateful for the collaborative work with MSD, and we are glad that the recruitment process remains on track. We all look forward to generating another encouraging data in a larger population setting."
For more information about the Phase II olinvacimab and pembrolizumab combo study for the treatment of mTNBC, please visit clinicaltrials.gov and search for the reference identifier NCT04986852
About PharmAbcine Inc.
PharmAbcine is a clinical-stage biotech company focusing on the development of fully human antibody therapeutics to treat neovascular disorders, tumors, and other medically unmet diseases. It provides therapeutic antibodies for a wide spectrum of indications from oncology, immuno-oncology, ophthalmology, pulmonology, to renal pathology.
PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine's advanced 3G expression system accommodates high levels of antibody production and steady reproducibility. With these cutting-edge technology platforms, it provides state-of-the art antibody generation services.
PharmAbcine also has unique knowhow in the area of the antibody production, early drug development, and clinical development.
For additional information about PharmAbcine, visit http://www.pharmabcine.com or follow us on Youtube and Linkedin.
For licensing deals, co-development, and collaboration in research or antibody discovery inquiries, please contact:
Business Development Team
E-mail: [email protected]
Office line: +82 70 4279 5100
For investor relations and public relations inquiries, please contact:
IR/PR Team
Paul Kim, Chief Financial Officer
E-mail: [email protected]
Office line: +82 70 4270 2632
Sungjun Park, Associate
E-mail: [email protected]
Office line: +82 70 4270 2637
SOURCE PharmAbcine
Share this article